ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

{"_buckets": {"deposit": "6f82efd9-365f-4743-8283-924b349bd5a0"}, "_deposit": {"id": "30416", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "30416"}, "status": "published"}, "_oai": {"id": "oai:nagoya.repo.nii.ac.jp:00030416", "sets": ["2518"]}, "item_9_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2020-08", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "3", "bibliographicPageEnd": "467", "bibliographicPageStart": "457", "bibliographicVolumeNumber": "82", "bibliographic_titles": [{"bibliographic_title": "Nagoya Journal of Medical Science"}]}]}, "item_9_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Neoadjuvant chemotherapy (NAC) using the combination of anthracycline and taxanes is the standard regimen for patients with primary breast cancer. Among the taxanes, conventional paclitaxel (PTX) and docetaxel have usually been adopted in the neoadjuvant or adjuvant setting. Nanoparticle albumin-bound paclitaxel (nab-PTX) is a solvent-free formulation that can be delivered to cancer cells at higher doses than conventional PTX. This study is a retrospective observational study in a single institution. We evaluated the efficacy and safety of nab-PTX followed by 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) in the neoadjuvant setting. In this study, 50 patients with primary breast cancer received nab-PTX (q3w, 260 mg/m^2 ± trastuzumab 6 mg/kg) followed by FEC (q3w, 5-fluorouracil 500 mg/m^2, epirubicin 100 mg/m^2, and cyclophosphamide 500 mg/m^2) prior to surgery. The efficacy was evaluated using the clinical response rate (CRR), pathological complete response (pCR) rate, and Ki67 labeling index. Safety was evaluated using the frequency of treatment-related adverse events and relative dose intensity (RDI). All patients received at least one course of chemotherapy. The CRR and pCR rate were 88.0% and 40.0%, respectively. The mean Ki67 labeling index was significantly decreased from 47.7% to 24.6% after NAC. The safety profiles were comparable with previously reported regimens, and high RDIs were obtained (97.2% for nab-PTX and 95.5% for FEC). This study illustrated the efficacy and tolerability of a neoadjuvant regimen of nab-PTX followed by FEC.", "subitem_description_type": "Abstract"}]}, "item_9_identifier_registration": {"attribute_name": "ID登録", "attribute_value_mlt": [{"subitem_identifier_reg_text": "10.18999/nagjms.82.3.457", "subitem_identifier_reg_type": "JaLC"}]}, "item_9_publisher_32": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Nagoya University Graduate School of Medicine, School of Medicine"}]}, "item_9_relation_43": {"attribute_name": "異版である", "attribute_value_mlt": [{"subitem_relation_type": "isVersionOf", "subitem_relation_type_id": {"subitem_relation_type_id_text": "http://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/823.html ", "subitem_relation_type_select": "URI"}}]}, "item_9_select_15": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_select_item": "publisher"}]}, "item_9_source_id_61": {"attribute_name": "ISSN(Online)", "attribute_value_mlt": [{"subitem_source_identifier": "2186-3326", "subitem_source_identifier_type": "ISSN"}]}, "item_9_source_id_7": {"attribute_name": "ISSN(print)", "attribute_value_mlt": [{"subitem_source_identifier": "0027-7622", "subitem_source_identifier_type": "ISSN"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Shizuku, Masato"}], "nameIdentifiers": [{"nameIdentifier": "101040", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Shibata, Masahiro"}], "nameIdentifiers": [{"nameIdentifier": "101041", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Shimizu, Yoshimi"}], "nameIdentifiers": [{"nameIdentifier": "101042", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Takeuchi, Dai"}], "nameIdentifiers": [{"nameIdentifier": "101043", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Mizuno, Yutaka"}], "nameIdentifiers": [{"nameIdentifier": "101044", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-09-04"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "08_Shizuku.pdf", "filesize": [{"value": "331.9 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 331900.0, "url": {"label": "08_Shizuku.pdf", "url": "https://nagoya.repo.nii.ac.jp/record/30416/files/08_Shizuku.pdf"}, "version_id": "40809c4a-9693-44fa-8007-03eab6796735"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "breast cancer", "subitem_subject_scheme": "Other"}, {"subitem_subject": "nab-PTX", "subitem_subject_scheme": "Other"}, {"subitem_subject": "FEC", "subitem_subject_scheme": "Other"}, {"subitem_subject": "neoadjuvant chemotherapy", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "departmental bulletin paper", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Clinical outcomes of neoadjuvant chemotherapy for patients with breast cancer: Tri-weekly nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide: a retrospective observational study.", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Clinical outcomes of neoadjuvant chemotherapy for patients with breast cancer: Tri-weekly nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide: a retrospective observational study."}]}, "item_type_id": "9", "owner": "1", "path": ["2518"], "permalink_uri": "https://doi.org/10.18999/nagjms.82.3.457", "pubdate": {"attribute_name": "公開日", "attribute_value": "2020-09-04"}, "publish_date": "2020-09-04", "publish_status": "0", "recid": "30416", "relation": {}, "relation_version_is_last": true, "title": ["Clinical outcomes of neoadjuvant chemotherapy for patients with breast cancer: Tri-weekly nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide: a retrospective observational study."], "weko_shared_id": null}
  1. C100 医学部/医学系研究科
  2. C100b 紀要
  3. Nagoya journal of medical science
  4. 82(3)

Clinical outcomes of neoadjuvant chemotherapy for patients with breast cancer: Tri-weekly nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide: a retrospective observational study.

https://doi.org/10.18999/nagjms.82.3.457
https://doi.org/10.18999/nagjms.82.3.457
ca35b000-f5d9-44f6-a1c0-faee7294c835
名前 / ファイル ライセンス アクション
08_Shizuku.pdf 08_Shizuku.pdf (331.9 kB)
Item type 紀要論文 / Departmental Bulletin Paper(1)
公開日 2020-09-04
タイトル
タイトル Clinical outcomes of neoadjuvant chemotherapy for patients with breast cancer: Tri-weekly nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide: a retrospective observational study.
著者 Shizuku, Masato

× Shizuku, Masato

WEKO 101040

Shizuku, Masato

Search repository
Shibata, Masahiro

× Shibata, Masahiro

WEKO 101041

Shibata, Masahiro

Search repository
Shimizu, Yoshimi

× Shimizu, Yoshimi

WEKO 101042

Shimizu, Yoshimi

Search repository
Takeuchi, Dai

× Takeuchi, Dai

WEKO 101043

Takeuchi, Dai

Search repository
Mizuno, Yutaka

× Mizuno, Yutaka

WEKO 101044

Mizuno, Yutaka

Search repository
キーワード
主題Scheme Other
主題 breast cancer
キーワード
主題Scheme Other
主題 nab-PTX
キーワード
主題Scheme Other
主題 FEC
キーワード
主題Scheme Other
主題 neoadjuvant chemotherapy
抄録
内容記述 Neoadjuvant chemotherapy (NAC) using the combination of anthracycline and taxanes is the standard regimen for patients with primary breast cancer. Among the taxanes, conventional paclitaxel (PTX) and docetaxel have usually been adopted in the neoadjuvant or adjuvant setting. Nanoparticle albumin-bound paclitaxel (nab-PTX) is a solvent-free formulation that can be delivered to cancer cells at higher doses than conventional PTX. This study is a retrospective observational study in a single institution. We evaluated the efficacy and safety of nab-PTX followed by 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) in the neoadjuvant setting. In this study, 50 patients with primary breast cancer received nab-PTX (q3w, 260 mg/m^2 ± trastuzumab 6 mg/kg) followed by FEC (q3w, 5-fluorouracil 500 mg/m^2, epirubicin 100 mg/m^2, and cyclophosphamide 500 mg/m^2) prior to surgery. The efficacy was evaluated using the clinical response rate (CRR), pathological complete response (pCR) rate, and Ki67 labeling index. Safety was evaluated using the frequency of treatment-related adverse events and relative dose intensity (RDI). All patients received at least one course of chemotherapy. The CRR and pCR rate were 88.0% and 40.0%, respectively. The mean Ki67 labeling index was significantly decreased from 47.7% to 24.6% after NAC. The safety profiles were comparable with previously reported regimens, and high RDIs were obtained (97.2% for nab-PTX and 95.5% for FEC). This study illustrated the efficacy and tolerability of a neoadjuvant regimen of nab-PTX followed by FEC.
内容記述タイプ Abstract
出版者
出版者 Nagoya University Graduate School of Medicine, School of Medicine
言語
言語 eng
資源タイプ
資源 http://purl.org/coar/resource_type/c_6501
タイプ departmental bulletin paper
ID登録
ID登録 10.18999/nagjms.82.3.457
ID登録タイプ JaLC
関連情報
関連タイプ isVersionOf
識別子タイプ URI
関連識別子 http://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/823.html
ISSN(print)
収録物識別子タイプ ISSN
収録物識別子 0027-7622
ISSN(Online)
収録物識別子タイプ ISSN
収録物識別子 2186-3326
書誌情報 Nagoya Journal of Medical Science

巻 82, 号 3, p. 457-467, 発行日 2020-08
著者版フラグ
値 publisher
戻る
0
views
See details
Views

Versions

Ver.1 2021-03-01 08:50:11.963242
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3